糖尿病中的遗留效应:是否存在长期获益?
本文为叙述性综述,汇总了主要糖尿病试验长期随访和观察性队列研究中支持与反对血糖遗留效应的证据,并概述其病理生理基础及转化研究。早期糖尿病试验和观察性队列研究提示早期血糖控制存在长期效应,但已确诊糖尿病患者的试验长期随访不支持该效应;遗留效应证据在微血管并发症上比大血管事件更明确。总体提示血糖遗留效应是糖尿病早期阶段赋予的长期获益或风险,随时间推移因血管改变和并发症发生而减弱。
要点
- 早期血糖控制可能带来长期获益,但已确诊糖尿病患者长期随访不支持遗留效应。
- 遗留效应在微血管并发症上的证据比大血管事件更明确。
- 遗留效应可能随血管改变和并发症发生而减弱。
核心结论
- 血糖遗留效应是糖尿病早期阶段赋予的长期获益或风险,随时间推移因血管改变和并发症发生而减弱。
研究设计与样本
- 叙述性综述,汇总主要糖尿病试验长期随访和观察性队列研究证据,并概述病理生理基础及转化研究。
主要发现
- 早期糖尿病试验和观察性队列研究提示早期血糖控制存在长期效应。
- 已确诊糖尿病患者的试验长期随访不支持遗留效应。
- 遗留效应证据在微血管并发症上比大血管事件更明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In this narrative review, we summarise the evidence for and against the glycaemic legacy effect from the long-term follow-up of major diabetes trials and observational cohort studies. We provide a summary of the pathophysiological basis for the legacy effect and discuss some translational research. Results from trials of early diabetes and observational cohort studies suggest that a long-term effect of early glycaemic control exists; however, long-term follow-up from trials in participants with established diabetes is not supportive. Additionally, findings for the legacy effect are more conclusive for microvascular complications than macrovascular events. Overall, these results suggest that the glycaemic legacy effect is a long-term benefit (or risk) conferred to individuals in the early stages of diabetes and which is muted over time as individuals' vasculature changes and they develop complications from diabetes.
引用
- Folz R, Laiteerapong N. The legacy effect in diabetes: are there long-term benefits? Diabetologia. 2021. PMID: 34392398. doi:10.1007/s00125-021-05539-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。